Sophia Genetics SA (SOPH)vsVeeva Systems Inc Class A (VEEV)
SOPH
Sophia Genetics SA
$4.97
-4.24%
HEALTHCARE · Cap: $371.96M
VEEV
Veeva Systems Inc Class A
$178.11
-0.56%
HEALTHCARE · Cap: $29.44B
Smart Verdict
WallStSmart Research — data-driven comparison
Veeva Systems Inc Class A generates 4035% more annual revenue ($3.20B vs $77.27M). VEEV leads profitability with a 28.4% profit margin vs -102.2%. VEEV earns a higher WallStSmart Score of 69/100 (B-).
SOPH
Avoid26
out of 100
Grade: F
VEEV
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for SOPH.
Margin of Safety
+25.9%
Fair Value
$238.92
Current Price
$178.11
$60.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 22.4% year-over-year
Conservative balance sheet, low leverage
Keeps 28 of every $100 in revenue as profit
Growing faster than its price suggests
Strong operational efficiency at 29.4%
16.0% revenue growth
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Elevated debt levels
Weak financial health signals
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : SOPH
The strongest argument for SOPH centers on Revenue Growth. Revenue growth of 22.4% demonstrates continued momentum.
Bull Case : VEEV
The strongest argument for VEEV centers on Debt/Equity, Profit Margin, PEG Ratio. Profitability is solid with margins at 28.4% and operating margin at 29.4%. Revenue growth of 16.0% demonstrates continued momentum.
Bear Case : SOPH
The primary concerns for SOPH are EPS Growth, Market Cap, Debt/Equity.
Bear Case : VEEV
The primary concerns for VEEV are P/E Ratio.
Key Dynamics to Monitor
SOPH carries more volatility with a beta of 1.14 — expect wider price swings.
SOPH is growing revenue faster at 22.4% — sustainability is the question.
VEEV generates stronger free cash flow (100M), providing more financial flexibility.
Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VEEV scores higher overall (69/100 vs 26/100), backed by strong 28.4% margins and 16.0% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Sophia Genetics SA
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Sophia Genetics SA (SOPH) is a pioneering leader in data-driven medicine, focusing on advanced genomic and clinical data analytics that enhance patient outcomes. Utilizing cutting-edge machine learning algorithms, the company provides a comprehensive platform that aids hospitals and laboratories in interpreting complex genomic data, thus facilitating personalized treatment strategies, especially in oncology, rare diseases, and hereditary disorders. With a strong international footprint and strategic partnerships with premier healthcare organizations, Sophia Genetics is committed to transforming healthcare through precision medicine, solidifying its position as a front-runner in the genomics landscape.
Veeva Systems Inc Class A
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Veeva Systems Inc. provides cloud-based software for the life sciences industry in North America, Europe, Asia Pacific, the Middle East, Africa, and Latin America. The company is headquartered in Pleasanton, California.
Visit Website →Compare with Other HEALTH INFORMATION SERVICES Stocks
Want to dig deeper into these stocks?